

Specification

Please add the following paragraphs on page 2 of the specification before the section entitled “Detailed description of the Invention.”


Brief Description of the Drawings

Figure 1 shows the cumulative food intake at 6 hours subjects administered saline/tween, 2-methoxy-N—(3-morpholin-4-yl-prolyl)-4-[3-(4-phenoxy-phenyl)-ureido]-benzamide (example 23), or N-(2-Diethylamino-ethyl)-4-[3-(4-trifluoromethoxy-phenyl)-ureido]-benzamide (example 47).

Claim listing


This listing of claims will replace all prior versions and listings of claims in the application:

Claim 1 (Currently Amended) A compound with the following structure (Formula I)



I

wherein -A- is a linker, which is selected from the group consisting of



and, wherein the linker -A- may be attached via either of the two free bonds to the Ar₁ group;


and R7 is the same or different and is hydrogen or a straight or branched C₁-C₄ alkyl or alkenyl group;


Ar₁ is an aryl or heteroaryl group;

R1 is a lower alkoxy group ~~alkyl-O-~~ with one to four carbon atoms,

R2 is an R1 group or hydrogen, an OH or an NH₂ group,

Q is selected from the group consisting of





R3 and R4 are the same or different selected from straight or branched alkyl, alkenyl or alkynyl groups with 1-8 carbon atoms; cycloalkyl groups with 3-7 carbon atoms; alkylcycloalkyl with 4-9 carbon atoms; alkylaryl groups; alkylheterocyclyl groups; the aryl, heterocyclyl and heteroaryl groups may be optionally substituted;

Alk is the same or a different alkyl, alkenyl or alkynyl group;
R3 and R4 may optionally be linked to each other, when possible, as indicated in Formula I;
and R3 and R4 may optionally join to form a heterocyclic ring further comprising oxygen or nitrogen atoms that may be inserted in the chain or ring in a chemically stable position;


R5 is selected from hydrogen, halogen, alkoxy (AlkO-), hydroxy, alkylamino (AlkNH-), dialkylamino (Alk₂N-), hydroxylalkyl, carboxamido (-CONH₂, -CONHAIk, -CONAIk₂), acylamido (-NHCO-Alk), acyl (-CO-Alk), - CHO, nitrile, alkyl, alkenyl, alkynyl, - SCH₃, partially or fully fluorinated alkyl, partially or fully fluorinated alkoxy or partially or fully fluorinated thioalkoxy groups;

more than one R5 group, same or different, may be present on Ar₁; when more than one § R5 or when one R5 and one R8 group are present they could be connected to each other, directly or with a suitable connecting moiety, to form rings;


each X being the same or different H, F, Cl, Br, I, -SCH₃, -CF₃, -OCF₃, -SCF₃, OCH₃, or lower alkyl or alkenyl group;

n is 1,2 or 3,

R8 is halogen, alkyl, alkenyl, alkynyl, cycloalkyl with 3-7 carbons, aryl (Ar), heteroaryl, heterocyclyl, alkylcycloalkyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkoxy, aryloxy, alkoxy, dialkylamino, -CONHAIk, - CONHAr -CONAIk₂, -NHCO-Alk, -NHCO-Ar, -CO-Alk, -CO-Ar, - SCH₃, partially or fully fluorinated alkyl, alkoxy or thioalkoxy,
or R8 has the structure



in which B is a single bond or a connecting moiety selected from the group consisting of:




which may be attached via either of the two free bonds to the Ar_t group;

Ar₂ is an aryl or heteroaryl group;


R6 is selected from hydrogen, halogen, alkoxy (AlkO-), hydroxy, alkylamino (AlkNH-), dialkylamino (Alk₂N-), hydroxylalkyl, carboxamido (-CONH₂, -CONHAalk, -CONAlk₂), acylamido (-NHCO-Alk), acyl (-CO-Alk), -CHO, nitrile, alkyl, alkenyl, alkynyl, -SCH₃, partially or fully fluorinated alkyl, partially or fully fluorinated alkoxy or partially or fully fluorinated thioalkoxy;

more than one R6 group, same or different, may be present on Ar₂; when more than one R6 group is present they could be connected to each other to form rings.

Claim 2. (Original) A compound according to claim 1, wherein Q is




Claim 3. (Currently Amended) A compound according to claim 1 or 2, wherein R8 is




Claim 4. (Previously Presented) A compound according to claim 1, wherein R8 is selected from halogen, alkyl, alkenyl, alkynyl, cycloalkyl groups with 3-7 carbons, aryl (Ar), heteroaryl, heterocyclyl, alkylcycloalkyl, alkylaryl, alkylheterocyclyl, alkylheteroaryl, arylalkoxy, aryloxy (ArO-), alkoxy (AlkO-), dialkylamino (Alk₂N-), -CONHAlk, -CONHAr, -CONAlk₂, -NHCO-Alk, -NHCO-Ar, -CO-Alk, -CO-Ar, -CF₃, -OCF₃, -SCF₃, or SCH₃.

Claim 5. (Previously Presented) A compound according to claim 1 any of the preceding claims wherein A is selected from the group consisting of:




wherein R7 is as defined in claim 1.

Claim 6. (Previously Presented) A compound according to claim 1 wherein A is selected from the group consisting of:




wherein R7 is as defined in claim 1.

Claim 7. (Previously Presented) A compound according to claim 1 wherein B is a single bond or selected from the group consisting of:




wherein R7 is as defined in claim 1.

Claim 8. (Previously Presented) A compound according to claim 7, wherein B is selected from the group consisting of:




wherein R7 is as defined in claim 1.

Claim 9. (Currently Amended) A The compound according to claim 1 with the following structure



wherein Ar₁, Ar₂, A, B, RI, R2, R3, R4, R5, R6, R7, R8, X and n are defined as in claim 1.

Claim 10. (Original) A compound according to claim 9, wherein R8 is



Claim 11. (Currently Amended) A The compound according to claim 1 wherein the -B- moiety is not placed ortho to the -A- linker.

Claim 12. (Currently Amended) A The compound according to claim 1, wherein Ar₁ and Ar₂ are the same or different aryl or heteroaryl groups such as, e.g., phenyl, pyridine, thiophene.

Claim 13. (Currently Amended) A The compound according to claim 1, wherein R2 is hydrogen.

Claim 14. (Previously Presented) A compound according to claim 1, wherein R2 is hydrogen and X is H, F, Cl, Br, I, CF₃, OCF₃, SCF₃, SCH₃ or lower alkyl or alkenyl group.

Claim 15. (Previously Presented) A compound according to claim 1, wherein R2 is H and X is H or F.

Claim 16. (Previously Presented) A compound according to claim 1, wherein R5 and R6 may be the same or different selected from hydrogen, halogen, alkoxy (AlkO-), alkyamino (AlkNH-), dialkylamino (Alk₂N-), carboxamido (-CONH₂, -CONHAlk, CONAlk₂), acylamido (-NHCO-Alk), nitrile, lower alkyl groups, -CF₃, -OCF₃, -SCF₃, -SCH₃.

Claim 17. (Previously Presented) A compound according to claim 1 in amorphous or crystalline form.

Claim 18. (Currently Amended) A compound according to claim 1 in racemic or enantiomeric \pm form.

Claim 19. (Previously Presented) A compound according to claim 1 in the form of a physiologically acceptable salt, complex, solvate or prodrug thereof.

Claims 20-44. (Canceled)

Claim 45. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 1 or a physiologically acceptable salt thereof together with one or more physiologically acceptable excipients.

Claim 46. (Previously Presented) A pharmaceutical composition according to claim 45, wherein the compound is present in the form of a physiologically acceptable salt an organic

acid.

Claim 47. (Previously Presented) A composition according to claim 45 for enteral and/or parenteral use.

Claim 48. (Previously Presented) A pharmaceutical composition according to claim 45 for oral, buccal, rectal, nasal, topical, vaginal or ocular use.

Claim 49. (Previously Presented) A pharmaceutical composition according to claim 45 in the form of a solid, semi-solid or fluid composition.

Claim 50. (Previously Presented) A pharmaceutical composition according to claim 49 in solid form, wherein the composition is in the form of one or more tablets.

Claim 51. (Original) A pharmaceutical composition according to claim 49 in semi-solid form, wherein the composition is in the form of a chewing gum, an ointment, a cream, a liniment, a paste, a gel or a hydrogel.

Claim 52. (Original) A pharmaceutical composition according to claim 49 in fluid form, wherein the composition is in the form of a solution, an emulsion, a suspension, a dispersion, a liposomal composition, a spray, a mixture, or a syrup.

Claim 53. (Currently Amended) A pharmaceutical composition according to claim 46 comprising a therapeutically effective amount of a compound according to claims.

Claim 54. (Previously Presented) A pharmaceutical composition according to claim 53, wherein the amount is from about 0.001 mg to about 1 g.

Claim 55. (Canceled)